TrialNature medicine2021

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.

Jingxin Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.